Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (SHE:301520)
China · Delayed Price · Currency is CNY 41.83
-4.08 (-8.89%)
At close: Aug 3, 2026
SHE:301520 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 233.67 | 274.18 | 379.09 | 341.81 | 260.78 | 211.09 |
Revenue Growth | -35.09% | -27.67% | 10.91% | 31.07% | 23.54% | 51.72% |
Gross Profit Gross Profit Growth | 53.2 | 71.01 | 150.04 | 167.27 | 131.39 | 111.27 |
Operating Income Operating Income Growth | -11.54 | 2.82 | 51.54 | 103.06 | 95.99 | 83.04 |
Net Income Net Income Growth | 24.32 | 36.43 | 85.53 | 108.09 | 98.73 | 81.87 |
Earnings Per Share EPS Growth | 0.26 | 0.39 | 0.91 | 1.43 | 1.41 | 1.17 |
EPS Growth | -63.91% | -57.03% | -36.00% | 1.53% | 20.12% | 43.85% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Clinical Research Services Clinical Research Services Growth | 217.94 | 303.67 | 243.69 | 188.12 | 149.73 |
Pharmaceutical Research Services Pharmaceutical Research Services Growth | 21.81 | 38.52 | 60.45 | 50.02 | 45.94 |
Other Other Growth | 34.43 | 36.9 | 37.67 | 22.64 | 4.76 |
Total Total Growth | 274.18 | 379.09 | 341.81 | 260.78 | 200.44 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,141 | 1,151 | 1,203 | 1,156 | 186.35 | 161.55 |
Total Debt Total Debt Growth | 2.42 | 1.6 | 1.6 | 1 | 0.03 | 0.15 |
Net Cash (Debt) Net Cash Growth | 1,138 | 1,149 | 1,201 | 1,155 | 186.32 | 161.41 |
Net Cash Growth | -1.54% | -4.31% | 3.97% | 520.08% | 15.43% | 34.49% |
Net Cash Per Share Net Cash Per Share Growth | 12.23 | 12.40 | 12.84 | 15.27 | 2.66 | 2.31 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 4.57 | -7.92 | 46.84 | 71.92 | 72.32 | 55.43 |
Capital Expenditures CapEx Growth | -20.17 | -19.22 | -41.82 | -85.97 | -50.7 | -15.6 |
Free Cash Flow Free Cash Flow Growth | -15.6 | -27.14 | 5.02 | -14.05 | 21.63 | 39.84 |
Free Cash Flow Growth | - | - | - | - | -45.71% | -1.01% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Gross Margin | 22.77% | 25.90% | 39.58% | 48.94% | 50.38% | 52.71% |
Operating Margin | -4.94% | 1.03% | 13.59% | 30.15% | 36.81% | 39.34% |
Pretax Margin | 9.55% | 13.08% | 23.61% | 35.00% | 42.62% | 44.69% |
Profit Margin | 10.41% | 13.29% | 22.56% | 31.62% | 37.86% | 38.78% |
FCF Margin | -6.68% | -9.90% | 1.32% | -4.11% | 8.29% | 18.87% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Dividend Per Share Dividend Per Share Growth | 0.214 | 0.214 | 0.250 | 0.357 |
Dividend Per Share Growth | 0% | -14.28% | -29.99% | - |
Dividend Yield | 0.47% | 0.76% | 0.92% | 0.93% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 160.06 | 72.26 | 30.01 | 34.11 | - | - |
P/FCF Ratio | - | - | 511.43 | - | - | - |
PS Ratio | 16.61 | 9.60 | 6.77 | 10.79 | - | - |